You have full text access to this OnlineOpen article
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole
Article first published online: 4 MAR 2013
© 2013 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 37, Issue 8, pages 810–818, April 2013
How to Cite
Aliment Pharmacol Ther 2013; 37: 810–818
- Issue published online: 18 MAR 2013
- Article first published online: 4 MAR 2013
- Manuscript Accepted: 8 FEB 2013
- Manuscript Revised: 29 JAN 2013
- Manuscript Revised: 12 NOV 2012
- Manuscript Received: 28 OCT 2012
- Takeda Global Research & Development Center, Inc
- Takeda Pharmaceuticals United States of America, Inc
- 4Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005; 100: 1243–50., , , et al.Direct Link:
- 10Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol 2008; 103: 1349–54., , , et al.Direct Link:
- 15Obesity increases oesophageal acid exposure.Gut 2007; 56: 749–55., , , et al.
- 18The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol 2007; 102: 2387–94., , , et al.Direct Link:
- 19Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole. Am J Gastroenterol 2008; 103: 2209–14., , , et al.Direct Link:
- 23Assessing the impact of body mass index (BMI) on the efficacy of proton pump inhibitors (PPIs) in GERD: a review of the literature. Am J Gastroenterol 2011; 106: S413., , , et al.
- 25Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment Pharmacol Ther 2009; 29: 731–41., , , et al.
- 28Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2011; 33: 213–24., , .
- 30Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis–results from the maintenance phase of the EXPO study. Aliment Pharmacol Ther 2009; 29: 1165–71., , , et al.